AD It UP: New Therapies for Managing Moderate to Severe Atopic Dermatitis

Learn how to help patients manage their atopic dermatitis through screening, education, and counselling.




Atopic dermatitis is one of the most common dermatological conditions that pharmacists see in practice. Moderate to severe AD has a significant impact on quality of life and does not respond well to topical therapies. There are now three indicated systemic therapies for these patients. Two of these treatments (tralokinumab and upadacitinib) were launched in Canada in 2021. This program will provide pharmacists with an update on new guidance on the management of moderate to severe AD and the potential role for these agents versus the current standard of care.

Learning objectives:

By the end of this course, you should be able to:  

  • Identify patients with moderate to severe atopic dermatitis (AD, eczema) who may require treatment adjustment or the addition of new agents to reach goals of therapy   
  • Review the impact of moderate to severe AD on a patient’s quality of life (itching, sleep, etc.)  
  • Discuss the limitations of topical therapies in managing patients with moderate to severe AD  
  • Determine which patients with AD should be referred to their primary care provider for changes to the AD treatment plan or the potential addition of new therapy  
  • Counsel patients on the different systemic therapy options for patients with moderate to severe AD

Course outline:

  • Webinar Recording (1 hour)
  • Final Exam (0.25 hour)
  • Program Evaluation


This learning activity has received financial support from Abbvie in the form of unrestricted educational grant. 

Course at a glance:

  • 1.25 hours to complete
  • 1 CEUs
  • Course expiration date: December 7, 2022
  • Online
  • Accreditation: 1177-2022-3398-I-P
  • Completion requirement: Complete the course’s online modules and achieve a score of 70 per cent on the multiple-choice exam.

Who should take this course:

Pharmacists who want to improve their knowledge of atopic dermatitis therapies.

Development Team:

  • Michael Boivin, BSc. Pharm
  • Melinda Gooderham, MD, FRCPC
  • Aaron Sihota, BSc. Pharm
  • Dan Tam Vu, B. Pharm